J. Goldman & Co’s Atara Biotherapeutics ATRA Stock Holding History

J. Goldman & Co’s Portfolio ATRA Stock Details ATRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-39,466	Closed	-$685K	–	444
2024 Q1	$685K	Buy	+39,466	New	+$701K	0.02%	302

Other funds holding ATRA

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Centiva Capital New York $11.5B AUM 31.97% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

J. Goldman & Co's ATRA Position: Q2 2024 in Review

J. Goldman & Co sold out of Atara Biotherapeutics (ATRA) in Q2 2024, closing a stake of 39,466 shares — an estimated $685K sold.

J. Goldman & Co first reported a position in ATRA in Q1 2024 and held it in 1 quarter. The position peaked at $685K in Q1 2024. 48 funds tracked by Wall St. Rank hold ATRA as of Q2 2024.

J. Goldman & Co reported no remaining Atara Biotherapeutics position as of Q2 2024 after selling out during the quarter.
J. Goldman & Co sold 39,466 Atara Biotherapeutics shares in Q2 2024, an estimated $685K.
J. Goldman & Co first reported a position in Atara Biotherapeutics in Q1 2024 and held it in 1 quarter.
J. Goldman & Co's Atara Biotherapeutics position peaked at $685K in Q1 2024.
48 funds tracked by Wall St. Rank held Atara Biotherapeutics as of Q2 2024.

Based on J. Goldman & Co's 13F filing for Q2 2024, filed 14 Aug 2024.